ECSP22091230A - Derivados de n-(piperidin-4-il)benzamida de acción luminal - Google Patents

Derivados de n-(piperidin-4-il)benzamida de acción luminal

Info

Publication number
ECSP22091230A
ECSP22091230A ECSENADI202291230A ECDI202291230A ECSP22091230A EC SP22091230 A ECSP22091230 A EC SP22091230A EC SENADI202291230 A ECSENADI202291230 A EC SENADI202291230A EC DI202291230 A ECDI202291230 A EC DI202291230A EC SP22091230 A ECSP22091230 A EC SP22091230A
Authority
EC
Ecuador
Prior art keywords
luminal
piperidin
action
benzamide derivatives
compounds
Prior art date
Application number
ECSENADI202291230A
Other languages
English (en)
Inventor
Tony S Gibson
Steve Swann
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of ECSP22091230A publication Critical patent/ECSP22091230A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4468Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/59Hydrogenated pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos de Fórmula 1 y sales farmacéuticamente aceptables de estos, en donde m, R1, R2, R3, R4, R5, R6, X1, X2, X3 y X4 se definen la memoria descriptiva. Esta descripción también hace referencia a materiales y métodos para la preparación de compuestos de Fórmula 1, a composiciones farmacéuticas que los contienen y a su uso para el tratamiento de enfermedades, trastornos y afecciones asociados con el receptor 5-HT4.
ECSENADI202291230A 2020-05-04 2022-11-28 Derivados de n-(piperidin-4-il)benzamida de acción luminal ECSP22091230A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063019829P 2020-05-04 2020-05-04
PCT/US2021/030493 WO2021225968A1 (en) 2020-05-04 2021-05-03 Luminally-acting n-(piperidin-4-yl)benzamide derivatives

Publications (1)

Publication Number Publication Date
ECSP22091230A true ECSP22091230A (es) 2023-02-28

Family

ID=76060006

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202291230A ECSP22091230A (es) 2020-05-04 2022-11-28 Derivados de n-(piperidin-4-il)benzamida de acción luminal

Country Status (17)

Country Link
US (1) US20230158010A1 (es)
EP (1) EP4146625A1 (es)
JP (1) JP2023525986A (es)
KR (1) KR20230005893A (es)
CN (1) CN115515933A (es)
AR (1) AR122005A1 (es)
AU (1) AU2021266690A1 (es)
BR (1) BR112022022184A2 (es)
CA (1) CA3182379A1 (es)
CL (1) CL2022003067A1 (es)
CO (1) CO2022015823A2 (es)
EC (1) ECSP22091230A (es)
IL (1) IL297456A (es)
MX (1) MX2022013745A (es)
PE (1) PE20231375A1 (es)
TW (1) TW202208333A (es)
WO (1) WO2021225968A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
KR100976063B1 (ko) * 2007-03-16 2010-08-17 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
KR20100026641A (ko) * 2008-09-01 2010-03-10 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법

Also Published As

Publication number Publication date
WO2021225968A1 (en) 2021-11-11
AU2021266690A1 (en) 2022-11-10
IL297456A (en) 2022-12-01
AR122005A1 (es) 2022-08-03
KR20230005893A (ko) 2023-01-10
BR112022022184A2 (pt) 2023-01-17
CA3182379A1 (en) 2021-11-11
PE20231375A1 (es) 2023-09-07
MX2022013745A (es) 2022-11-16
JP2023525986A (ja) 2023-06-20
CL2022003067A1 (es) 2023-07-14
EP4146625A1 (en) 2023-03-15
TW202208333A (zh) 2022-03-01
US20230158010A1 (en) 2023-05-25
CO2022015823A2 (es) 2022-11-18
CN115515933A (zh) 2022-12-23

Similar Documents

Publication Publication Date Title
UY38602A (es) Compuestos tricíclicos condensados
ECSP20070854A (es) Compuestos heteroaril tetracíclicos
ECSP20062464A (es) Piperidinil-3-(ariloxi)propanamidas y propanoatos
UY31471A1 (es) Derivados bis-(sulfonilamino) en terapia 066
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
DOP2022000057A (es) Derivados de piridazin-3(2h)-ona fusionados con azol
PA8575401A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso
GT199800180A (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos.
AR030959A1 (es) Derivados de aminoalcoholes, procedimiento para prepararlos, el uso de los mismos para preparar medicamentos y las composiciones farmaceuticas que las contienen
PA8547901A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
AR067779A1 (es) Profarmacos dipeptoides y su uso
DOP2006000243A (es) Derivados de pirazina
CO2021014155A2 (es) Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2
AR127050A1 (es) Compuestos espirocíclicos
CO5611124A2 (es) Derivados de benzofurano substituidos utiles en el tratamiento de desordenes hiper-proliferativos
ECSP22049160A (es) Derivados de bencimidazol
ECSP22091230A (es) Derivados de n-(piperidin-4-il)benzamida de acción luminal
CO2023000117A2 (es) Derivados de sulfona
AR124720A1 (es) Derivados de pirazolamida
ECSP22082217A (es) Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida
ECSP22082219A (es) Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina
AR049638A1 (es) Derivados de benzileter, su elaboracion, su uso para preparar agentes farmaceuticos y composicion farmaceutica
AR128930A1 (es) Derivados de n-(pirrolidin-3-il o piperidin-4-il)acetamida
ECSP992872A (es) Derivados de 2-ariletil - (piperidin - 4-- ilmetil) amina
ECSP972047A (es) Nuevos derivados de arilglicinamida, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos